Clinical status of carboplatin.
作者信息
Canetta R, Franks C, Smaldone L, Bragman K, Rozencweig M
机构信息
Bristol-Myers Company, Pharmaceutical Research and Development Division, Wallingford, Connecticut.
出版信息
Oncology (Williston Park). 1987 Jul;1(5):61-70.
PMID:3079484
Abstract
Carboplatin, a cisplatin derivative, shows promise of being an effective weapon against ovarian, cervical, and small-cell lung cancer, as well as epidermoid cancer of the head and neck, with fewer toxic effects than cisplatin. It has successfully completed phase III investigation and clinical trials continue.
摘要
Zotero 插件